Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phesgo
- Development stage
- Approved
- Lead developer
- Roche
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Phesgo is a fixed-dose combination biologic therapy containing two HER2-targeting monoclonal antibodies, pertuzumab and trastuzumab, along with hyaluronidase-zzxf, an enzyme that facilitates subcutaneous administration. Developed by Roche and its subsidiary Genentech, Phesgo is FDA-approved for the treatment of HER2-positive breast cancer. In the context of prostate cancer, the Mayo Clinic is investigating Phesgo in the Phase II TraPPer trial (NCT05730712) in combination with enzalutamide for patients with enzalutamide-refractory metastatic castration-resistant prostate cancer (mCRPC). The study aims to determine if dual HER2 blockade can overcome resistance to androgen receptor signaling inhibitors in this patient population. The subcutaneous delivery of Phesgo offers a more convenient administration route compared to traditional intravenous infusions of its individual components.
- Brand names
- Phesgo
- Other names
- pertuzumab + trastuzumab + hyaluronidase-zzxfHP
02
Targets
HER2 ECD subdomain II (Human epidermal growth factor receptor 2 dimerization interface)
Beyond the preview
Go deeper on Phesgo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phesgo.